NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

Phase 2

Active, not recruiting

Conditions: Kidney Transplant
COVID-19

Interventions: Biological: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

First Posted Date: 2022-08-26

Last Posted Date: 2024-04-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT05518487

Locations: 🇺🇸
University of California San Diego Medical Center: Transplantation, San Diego, California, United States
🇺🇸
Emory University School of Medicine: Transplantation, Atlanta, Georgia, United States
🇺🇸
UCSF School of Medicine: Transplantation, San Francisco, California, United States

and more 3 locations

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

Phase 2

Completed

Conditions: Monkeypox

Interventions: Biological: JYNNEOS

First Posted Date: 2022-08-23

Last Posted Date: 2024-10-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 229

Registration Number: NCT05512949

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 5 locations

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Phase 1

Active, not recruiting

Conditions: Campylobacter Infection

Interventions: Drug: ALFQ
Biological: CJCV2

First Posted Date: 2022-08-15

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 59

Registration Number: NCT05500417

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States

Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III

Completed

Conditions: Ebola Virus Disease

First Posted Date: 2022-08-10

Last Posted Date: 2025-01-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 203

Registration Number: NCT05494801

Locations: 🇱🇷
John F. Kennedy Medical Center, Monrovia, Liberia

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Phase 1

Completed

Conditions: HIV

Interventions: Biological: Trimer 6931 (100 mcg)
Biological: FP conjugate vaccine (200 mcg)
Biological: Trimer 6931 (200 mcg)
Biological: Trimer 4571 (200 mcg)
Biological: FP conjugate vaccine (25 mcg)
Biological: Trimer 4571 (100 mcg)

First Posted Date: 2022-07-22

Last Posted Date: 2024-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT05470400

Locations: 🇺🇸
BIDMC Vcrs [32077], Boston, Massachusetts, United States
🇺🇸
New York Blood Center CRS [31801], New York, New York, United States
🇺🇸
Atlanta - Hope Clinic, Atlanta, Georgia, United States

and more 3 locations

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum in Healthy, HIV-1 Uninfected Adult Participants

Phase 1

Active, not recruiting

Conditions: HIV-1-infection

Interventions: Biological: 426c.Mod.Core-C4b 30 mcg
Other: Placebo
Biological: BG505
Biological: 426c.Mod.Core-C4b 100 mcg
Biological: 426c.Mod.Core-C4b 300 mcg

First Posted Date: 2022-07-22

Last Posted Date: 2023-11-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT05471076

Locations: 🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States

and more 3 locations

Neonatal Phase 1 Valacyclovir Study

Phase 1

Recruiting

Conditions: Herpes Simplex

Interventions: Drug: Valacyclovir

First Posted Date: 2022-07-21

Last Posted Date: 2025-01-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT05468619

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States
🇺🇸
Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease, Queens, New York, United States

and more 9 locations

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease

Interventions: Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Alemtuzumab
Drug: Busulfan
Biological: Pheripheral blood stem cells
Drug: Tociluzumab
Drug: Emapalumab-Izsg
Drug: Total Body Irradiation

First Posted Date: 2022-07-18

Last Posted Date: 2024-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT05463133

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Phase 1

Recruiting

Conditions: Bacterial Disease Carrier
Cystic Fibrosis

Interventions: Biological: WRAIR-PAM-CF1
Other: Placebo

First Posted Date: 2022-07-12

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT05453578

Locations: 🇺🇸
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States
🇺🇸
University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸
University of California Davis Health, Sacramento, California, United States

and more 14 locations

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Phase 4

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Vanicream- Experienced Dupilumab
Biological: Dupilumab
Drug: Vanicream- Active
Drug: Vanicream- Dupilumab-naïve
Drug: Triamcinolone Acetonide
Drug: Hydrocortisone

First Posted Date: 2022-06-29

Last Posted Date: 2024-10-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 600

Registration Number: NCT05436535

Locations: 🇺🇸
Children's Hospital Los Angeles: Division of Clinical Immunology & Allergy, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Perelman Center for Advanced Medicine: Department of Dermatology, Philadelphia, Pennsylvania, United States
🇺🇸
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Chapel Hill, North Carolina, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy